55
Participants
Start Date
July 31, 2016
Primary Completion Date
September 30, 2017
Study Completion Date
September 30, 2017
MLE4901
For 80% of subjects randomized to MLE4901 (n=24/30), the dose is 40 mg twice daily. Six subjects (20%) randomized to higher MLE4901 dose cohorts that were promptly discontinued.
Placebo
Placebo to match active drug
Upstate Clinical Research Associates, Williamsville
The Pennsylvania State University (Penn State) Milton S. Hershey Medical Center, Hershey
Main Line Fertility and Reproductive Medicine, Bryn Mawr
University of Pennsylvania Perelman Center for Advanced Medicine - Penn Fertility Care, Philadelphia
Charlottesville Medical Research Center, LLC, Charlottesville
Tidewater Clinical Research, Inc., Norfolk
PMG Research of Cary, Cary
Magnolia OB/GYN Research Center, Myrtle Beach
Atlanta Women's Research Institute, Atlanta
University of Florida (UF), Jacksonville
Avail Clinical Research, LLC, DeLand
Compass Research, LLC, Orlando
Health Care Family Rehab & Research Center, Hialeah
Segal Institute for Clinical Research, North Miami
Palmetto Professional Research, Miami
Stedman Clinical Trials, LLC, Tampa
Aventiv Research, Inc., Columbus
Rapid Medical Research, Inc., Cleveland
University Hospitals Cleveland Medical Center, Mayfield Heights
Clinical Research of Tiffin, Tiffin
Montana Health Research Institute, Inc., Billings
Womens Health Practice, Champaign
GTC Enterprises LLC, Shawnee Mission
NEA Baptist Clinic, Jonesboro
Texas Diabetes and Endocrinology, P.A. - South Austin, Austin
Advanced Clinical Research, Boise
Wasatch Clinical Research, Salt Lake City
Highland Clinical Research, Salt Lake City
Hope Research Institute, LLC, Phoenix
Excell Research, Oceanside
Clinical Research Consulting, LLC, Milford
Lead Sponsor
Collaborators (2)
Medpace, Inc.
INDUSTRY
Covance
INDUSTRY
Millendo Therapeutics US, Inc.
INDUSTRY